← Back to Search

Electroconvulsive Therapy

ECT vs. Ketamine for Depression (REaKT-SD Trial)

Phase 4
Waitlist Available
Led By Amit Anand, MD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Meet DSM-5 criteria for Major Depressive Episode (MDE) as determined by Mini International Neuropsychiatric Interview (MINI PLUS 5.0.0)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks
Awards & highlights

REaKT-SD Trial Summary

This trial compares two treatments for suicidal depression: ECT and KET. It measures which works best.

Who is the study for?
This trial is for adults aged 18-90 with acute suicidal depression who are candidates for ECT treatment. Participants must show ongoing suicidal thoughts and meet criteria for a major depressive episode, but not have schizophrenia or severe cognitive impairment. Pregnant individuals, those unable to consent, or with certain medical conditions like uncontrolled illness or ketamine allergy cannot join.Check my eligibility
What is being tested?
The study compares the effectiveness of Electroconvulsive therapy (ECT) versus intravenous Ketamine (KET) in treating acute suicidal depression. It's randomized and single-blind, meaning participants won't know which treatment they receive but researchers will.See study design
What are the potential side effects?
ECT may cause temporary confusion, memory loss, physical side effects like headaches or muscle aches. Ketamine can lead to dissociation (feeling detached from reality), dizziness, nausea, increased blood pressure and potentially abuse due to its psychoactive properties.

REaKT-SD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a major depressive episode.

REaKT-SD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Scale for Suicidal Ideation (SSI)
Secondary outcome measures
Brief Psychiatric Rating Scale 4 items (BPRS)
CGI-I
CGI-S
+19 more

REaKT-SD Trial Design

2Treatment groups
Active Control
Group I: Electroconvulsive therapy (ECT)Active Control1 Intervention
ECT will be given in a standard manner 3 times a week for 4 weeks.
Group II: Subanesthetic dose intravenous ketamine (KET)Active Control1 Intervention
This trial will use standard dose of ketamine (0.5mg/kg infusion over 40 min period) in accordance with research studies that have used ketamine as an antidepressant.

Find a Location

Who is running the clinical trial?

The Cleveland ClinicOTHER
1,026 Previous Clinical Trials
1,364,576 Total Patients Enrolled
Baylor College of MedicineOTHER
1,001 Previous Clinical Trials
6,000,752 Total Patients Enrolled
The University of Texas Health Science Center, HoustonOTHER
903 Previous Clinical Trials
319,477 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the age requirement for participating in this experiment extend beyond 40 years?

"For this medical trial, individuals who are aged between 18 and 90 may be eligible for recruitment."

Answered by AI

Has the FDA approved Electroconvulsive therapy (ECT) for clinical use?

"As ECT is an approved therapy, our team at Power rated its safety level a 3 on the 1-3 scale."

Answered by AI

How broadly is the research being conducted in this state?

"Nine different clinical trial sites across the United States are currently enrolling patients in this medical study. Major cities with locations include Baltimore, New york and Saint Louis; other locations may be closer to you if travel is a factor for your participation."

Answered by AI

Are there any opportunities for enrolment in this clinical trial currently available?

"The information hosted on clinicaltrials.gov denotes that this medical trial is not forging ahead with patient recruitment at the moment. Initially posted on October 1st 2023, and having undergone its last update on September 28th of the same year, it stands in contrast to 1216 other studies presently seeking participants."

Answered by AI

Who meets the qualifications to participate in this clinical trial?

"This clinical study is recruiting 1500 persons aged 18 to 90 who are living with acute depression. Candidates must meet the following criteria: a score of 15 or higher on the Hamilton Depression Scale, Montreal Cognitive Assessment (MoCA) scores greater than 23, expressing suicidal intent as evidenced by a minimum SSI score of 6, referral for electroconvulsive therapy treatment from an in-person assessment, and diagnosis meeting DSM-5 Major Depressive Episode criteria via MINI PLUS 5.0.0 evaluation."

Answered by AI

Who else is applying?

What site did they apply to?
Johns Hopkins University
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan
Amit Anand 2023. "Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06034821.
~1000 spots leftby Jan 2030
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top